Case Report

Persistently positive PCR SARS-CoV-2 at low cycle threshold in an immunosuppressed patient

Rosa-María Martín-Díaz a,*, Jon Cabrejas-Ugartondo a, Mar Iglesias-López b, Beatriz Chulvi-Calvo a, Desirée Vélez-Rodriguez a

a Sureste Hospital, Department of Internal Medicine, Arganda del Rey, Madrid, Spain
b Sureste Hospital, Department of Continuity Care, Arganda del Rey, Madrid, Spain

ARTICLE INFO

Article history:
Received 29 April 2022
Accepted 5 August 2022
Available online 22 August 2022

Keywords:
SARS-CoV-2
Persistently positive PCR
Low cycle threshold
Immunosuppressed

ABSTRACT

We describe the very prolonged course of the disease in an immunosuppressed patient with persistently positive PCR against SARS-CoV-2 with low cycle threshold for at least 114 days.

© 2022 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

During the COVID19 pandemic, we have learned that certain conditions can lead not only to a poor prognosis, but also to a prolonged course of the disease. Immunosuppressed patients, especially those with hematological malignancies and/or certain immunosuppressive treatments such as anti-CD20 monoclonal antibodies have been described at particularly high risk.1,2

We report a patient diagnosed with non-Hodgkin’s lymphoma who had completed her treatment with rituximab 4 months earlier with no signs of relapse, who was diagnosed with COVID-19 infection and persisted with PCR against SARS-CoV-2 with low cycle threshold (ct) in nasopharyngeal swabs for at least 114 days.

Case description

Herein, we report a 70-year-old woman who had been diagnosed with follicular non-Hodgkin’s lymphoma three years earlier, having followed a 6-cycle course of R-CHOP followed by a bimonthly course of rituximab as maintenance that ended four months earlier with no signs of disease (last axial computerized tomography performed five days before symptoms onset). She received the first dose of the SARS-CoV-2 vaccine (mRNA-1273) six days before symptoms onset.

On day 1 of symptoms, she presented with general malaise, low-grade fever and arthralgias. On day 3, an antigen test was performed with a positive result.

On day 19, she attended the emergency department with a 3-day history of fever and worsening general malaise. She was breathing 97% room air, her chest radiograph showed peripheral opacities in the right middle and lower lobes and subtle opacities in the left lung. Her analyses showed normal D-dymer, a C-Reactive Protein (CRP) of 46.5 mg/dL

* Corresponding Author.
E-mail address: rmartindiaz@salud.madrid.org
(R.-M. Martín-Díaz).
https://doi.org/10.1016/j.bjid.2022.102696
1413-8670/© 2022 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
(cutoff 5 mg/dL), 400 lymphocytes/µL, and Lactate Dehydrogenase (LDH) 276 U/L (cutoff 120–246 U/L) as the most relevant findings. Urine antigens against *L. pneumophila* and *S. pneumoniae* were negative. She was admitted to hospital and meropenem plus linezolid were started empirically. Due to persistence of fever at 48 hours and having negative procalcitonin levels and sterile blood cultures, antibiotics were discontinued, and dexamethasone was started with disappearance of fever and general improvement within a few days, as well as laboratory improvement at discharge.

On day 34 (one day after discontinuation of steroid treatment) she was readmitted for dry cough and reappearance of fever. Her peripheral saturation was 93% in room air. Her blood test showed CPR 89.8 mg/dL, LDH 373 U/L, D-dymer 1350 ng/mL (cutoff 500 ng/mL), and 400 lymphocytes/µL. A chest CT showed bilateral pulmonary infiltrates, ground glass opacities and no signs of pulmonary thromboembolism. PCR against *SARS-CoV-2* was positive (15.46 ct, B.1.617.2 variant). Dexamethasone was restarted due to the previous good response. During admission, the search for microorganisms and malignancy in peripheral blood samples and a bronchoscopy were unsuccessful and serology against *SARS-CoV-2* reported the absence of antibodies. Clinically, the fever disappeared, the required oxygen flow was reduced, and the patient was discharged on a slow tapering course of dexamethasone, cotrimoxazole at a prophylactic dose, oxygen at 0.5 liters per minute and enoxaparin for the first days. In the follow-up we highlight oral sores due to HSV type 1 treated with acyclovir, intermittent discontinuation of supplemental oxygen and development of chilblain-like lesions on the hands.

On day 81 she was readmitted for popliteal deep vein thrombosis and segmental pulmonary embolism. *SARS-CoV-2* PCR was positive at 15.75 ct. An immunophenotypic study of the peripheral blood was consistent with previous rituximab treatment (absence of CD19+ B population and a slight inversion of the CD4/CD8 ratio). She also had a blood viral load for cytomegalovirus of 65,000 copies per milliliter, in the absence of retinitis, colitis or pneumonitis, so acyclovir was changed to valganciclovir with a drop in viral load in the following days. She also had a *P. aeruginosa* urinary tract infection, treated with piperacillin-tazobactam according to the antibiogram. Regarding the COVID infection itself, given the persistence of low ct, the therapeutic approach was reconsidered, and steroids were discontinued on day 99 of symptoms.

On day 106 she presented again urinary tract infection symptoms, and a more resistant strain of *P. aeruginosa* was isolated in urine culture, treated with ceftazidine-avibactam and amikacin. Her PCR for *SARS-CoV-2* was persistently positive (20.42 ct). After initial improvement, fever reappeared, and her respiratory status worsened. A body CT scan showed greater involvement of the lung parenchyma and bilateral pleural effusion. As a consequence, she was admitted to ICU on day 114, with *SARS-CoV-2* PCR positive for less than 20 cycles (quantification not reported). Convalescent plasma, linezolid, voriconazole, cotrimoxazole, ganciclovir and high-flow nasal cannula oxygen therapy were prescribed. Bronchoscopy was performed without respiratory secretions or endobronchial lesions and with negative cultures and *P. jiroveci* test.

The evolution was not adequate, presenting multiorgan failure and progressive respiratory worsening that required a change to mechanical ventilation and prone sessions with increasing difficulty for effective ventilation, respiratory acidosis and decreasing PaFi. The patient finally died on the 136th day of symptoms.

### Discussion

To our knowledge, relatively few cases of immunosuppressed patients with oncohematological malignancies and prolonged disease courses have been described.

In our experience, despite the good initial response to steroid treatment, which was attributed to its anti-inflammatory effect, it did not show a beneficial effect on the course of the disease. Given her persistent low ct, which was expected to correlate with viral persistence and activity, her impaired immunity by immunophenotypic study highlighting the immunosuppressive effect of previous rituximab, and considerations suggesting that steroids could prolong the viremic phase, we discontinued them and considered alternative approaches.

Studies and reports have been published with different treatments, including several monoclonal antibodies, immunoglobulins, remdesivir and convalescent plasma, but few of them focused in immunosuppressed patients with prolonged disease courses with diverse results. Although these treatments were considered, they were not prescribed on first attempt, mainly due to non-availability, difficulty in prescribing them as they were not included in the protocols and expected procoagulability. During the course, given the deterioration of the situation and the lack of effective measures, the patient could be included in an external clinical trial and convalescent plasma was administrated, without improvement.

The advent of vaccines has been a major breakthrough in the management of *SARS-CoV-2* disease, with reduced severity and improved prognosis. Undoubtedly, this is especially important in immunosuppressed patients with poorer prognosis and response to conventional treatments.

Not only are prolonged disease courses associated with poor patient outcomes, but it has also been observed that these patients may have mutations in the virus sequences during the course of the disease, which could eventually facilitate the emergence of new *SARS-CoV-2* variants with the consequent public health problems derived from them. In addition, observations have recently emerged about the possibility of promoting escape variants with convalescent plasma treatment and other treatments.

In conclusion, special considerations must be taken when in the treatment of immunosuppressed patients due to their greater susceptibility to more severe and prolonged disease courses, and we must continue to investigate effective treatments not only for the benefit of the patient, but also to decrease the possibility that new variants emerge with global implications.

### Ethical approval statement

This manuscript represents a descriptive case, and not an experimental study. Treatment was guided by local protocols.
and informed consent was obtained from the patient prior to publication of this case report.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;17:2881–92.
2. Arcani R, Colle J, Cauchois R, et al. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue. Ann Hematol. 2021;100:2799–803.
3. Thornton CS, Huntley K, Berenger BM, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022;11:28.
4. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infectivity: When is it safe to discontinue isolation? Clin Infect Dis. 2021;6:1467–74.
5. Veredese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: a real-world experience. Clin Infect Dis. 2022;74:1063–9.
6. Ljungquist O, Lundgren M, Iliachenko E, et al. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. Infect Dis. 2022;54:283–91.
7. Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study. Open Forum Infect Dis. 2021;8:1–7.
8. Bailly B, Péret H, Veyer D, et al. Persistent COVID-19 in an immunocompromised host treated by SARS-CoV-2-specific monoclonal antibodies. Clin Infect Dis. 2021. ciab668. [Preprint].
9. García-Vidal C, Iglesias-Caballero M, Puerta-Alcalde P, et al. Emergence of progressive mutations in SARS-CoV-2 from a hematologic patient with prolonged viral replication. Front Microbiol. 2022;13:1–5.
10. Scherer EM, Babiker A, Adelman MW, et al. SARS-CoV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. 2022;23:2436–8.
11. Sonnleitner ST, Prelog M, Sonnleitner M, et al. Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nat Commun. 2022;13:2560.
12. Caccuri F, Messali S, Bortolotti D, et al. Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host. Virus Evol. 2022;8:veac042.
13. Sabin AP, Richmond CS, Kenny PA. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. Diagn Microbiol Infect Dis. 2022;103:115656.
14. Lang-Meli J, Fuchs J, Mathé P, et al. Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency. J Clin Immunol. 2022;42:253–65.
15. Chen L, Zody MC, Di Germanio C, et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. mSphere. 2021;25:e0048021.